A Primary Health Care Program and COVID-19. Impact in Hospital Admissions and Mortality.

ingentiumby ingentium

In Clinical Literature.

Publication date: Jul 18, 2024

Most patients with mild or moderate COVID infection did not require hospital admission, but depending on their personal history, they needed medical supervision. In monitoring these patients in primary care, the design of specific surveillance programs was of great help. Between February 2021 and March 2022, EDCO program was designed in Tenerife, Spain, to telemonitor patients with COVID infection who had at least one vulnerability factor to reduce hospital admissions and mortality. The aim of this study is to describe the clinical course of patients included in the EDCO program and to analyze which factors were associated with a higher probability of hospital admission and mortality. Retrospective cohort study. We included 3848 patients with a COVID-19 infection age over 60 years old or age over 18 years and at least one vulnerability factor previously reported in medical history. Primary outcome was to assess risk of admission or mortality. 278 (7. 2%) patients required hospital admission. Relative risks (RR) of hospital admission were oxygen saturation ≤ 92% (RR: 90. 91 (58. 82-142. 86)), respiratory rate ≥ 22 breaths per minute (RR: 20. 41 (1. 19-34. 48), obesity (RR: 1. 53 (1. 12-2. 10), chronic kidney disease (RR:2. 31 (1. 23-4. 35), ≥ 60 years of age (RR: 1. 44 (1. 04-1. 99). Mortality rate was 0. 7% (27 patients). Relative risks of mortality were respiratory rate ≥ 22 breaths per minute (RR: 24. 85 (11. 15-55. 38), patients with three or more vulnerability factors (RR: 4. 10 (1. 62-10. 38), oxygen saturation ≤ 92% (RR: 4. 69 (1. 70-15. 15), chronic respiratory disease (RR: 3. 32 (1. 43-7. 69) and active malignancy (RR: 4. 00 (1. 42-11. 23). Vulnerable patients followed by a primary care programme had admission rates of 7. 2% and mortality rates of 0. 7%. Supervision of vulnerable patients by a Primary Care team was effective in the follow-up of these patients with complete resolution of symptoms in 91. 7% of the cases.

Open Access PDF

Concepts Keywords
February COVID-19
Hospital mortality
Kidney telemedicine
Malignancy vulnerability factors

Semantics

Type Source Name
disease MESH COVID-19
disease MESH infection
disease IDO history
disease MESH clinical course
drug DRUGBANK Oxygen
disease MESH obesity
disease MESH chronic kidney disease
disease MESH malignancy
disease VO effective
disease MESH death
disease VO vaccination
disease IDO blood
disease VO protocol
disease MESH emergency
disease VO population
disease VO time
disease MESH morbidity
disease MESH hypertension
disease MESH Alzheimer’s disease
disease MESH epilepsy
disease MESH stroke
drug DRUGBANK Trihexyphenidyl
drug DRUGBANK Profenamine
disease MESH brain tumors
disease MESH multiple sclerosis
disease MESH ischemic heart disease
disease VO URE
disease MESH cardiomyopathy
disease MESH COPD
disease MESH asthma
pathway KEGG Asthma
disease MESH fibrosis
disease MESH syndrome
disease MESH chronic bronchitis
disease MESH pulmonary emphysema
disease MESH bronchiectasis
disease MESH alcoholic steatohepatitis
disease MESH liver disease
disease IDO immunosuppression
drug DRUGBANK Etoperidone
disease MESH hypotension
drug DRUGBANK Coenzyme M
disease VO USA
disease MESH diabetes mellitus
disease IDO symptom
disease VO vaccinated
disease VO dose
disease VO vaccine
disease MESH Comorbidity
disease VO immunization
disease MESH pneumonia
drug DRUGBANK Azelaic acid
drug DRUGBANK L-Alanine
disease MESH lymphopenia
disease MESH thrombopenia
disease VO dead
drug DRUGBANK Creatinine
disease MESH tachypnea
drug DRUGBANK Fibrinogen Human
drug DRUGBANK Trestolone
disease MESH respiratory infections
disease VO vaccine dose
drug DRUGBANK BK-MDA
drug DRUGBANK Troleandomycin
drug DRUGBANK L-Valine
disease MESH Sepsis
disease MESH Septic Shock
disease VO effectiveness
disease MESH Respiratory Diseases
disease MESH Viral Diseases
drug DRUGBANK Sulfasalazine
disease MESH cardiovascular disease
drug DRUGBANK Glycine
disease MESH Arteriosclerosis

Original Article

(Visited 3 times, 1 visits today)